CYP19A1 and breast cancer: For breast cancer patients the American Society of Clinical Oncologists recommends that bone mineral density screening should be repeated annually in all patients receiving aromatase inhibitor adjuvant therapy, and bisphosphonate therapy should be initiated when the Bone Mineral Density Measurement which is commonly reported in terms of T-score, are -2.5 or lower [28].